2026-01-13 - Analysis Report
**Eli Lilly and Co (LLY) Financial Report**
=====================================================

### Overview
Eli Lilly and Co is a multinational pharmaceutical corporation.

### Stock Performance Comparison

* **Cumulative Return (%)**:
	+ Review Stock (LLY): **281.90%**
	+ Comparison Stock (VOO): **94.34%**
* **Divergence**:
	+ Degree of Divergence: **181.70**
	+ Relative Divergence: **80.50%**

### CAGR and Beta Analysis

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|-----|-------|------|--------|
| 2016-2018 | 37.0% | 14.3% | 33.0% | 0.7 | 103.7B |
| 2017-2019 | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020 | 30.0% | 20.9% | 10.0% | 0.7 | 151.4B |
| 2019-2021 | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022 | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023 | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024 | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025 | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

### Recent Stock Price Fluctuations

* **Close**: $1,081.00
* **5-day SMA**: $1,080.38
* **20-day SMA**: $1,068.69
* **60-day SMA**: $992.54
* **Last-market**: 
	+ **Price**: 1081.0
	+ **PreviousClose**: 1063.56
	+ **Change**: 1.64

### Indicator Analysis

* **Market Risk Indicator (MRI)**: 0.80
* **RSI**: 52.44
* **PPO**: -0.29
* **Hybrid Signal**: Buy
* **Recent (20 days) relative divergence change**: -3.40
* **7-day Rank change**: 0
* **7-day Dynamic Expected Return change**: 4.80
* **Expected Return (%)**: 52.10%

### Recent News & Significant Events

* [2026-01-12] Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030
* [2026-01-09] Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences
* [2026-01-12] This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest.
* [2026-01-12] Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
* [2026-01-11] This Healthcare Stock Could Be One of the Best Companies to Own in 2026
* [2026-01-09] Eli Lilly vs. Novo Nordisk: Which Is the Best Stock to Buy Today?

### Analyst Opinions

* **Analyst Consensus:**
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 1.70
	+ Opinions: 27
	+ Target Price (avg/high/low): 1116.33 / 1500.00 / 770.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

### Financial Information

#### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | 17.60B | 82.91% |
| 2025-06-30 | 15.56B | 84.27% |
| 2025-03-31 | 12.73B | 82.53% |
| 2024-12-31 | 13.53B | 82.24% |
| 2024-09-30 | 11.44B | 81.02% |

#### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | 23.79B | 23.46% |
| 2025-06-30 | 18.27B | 30.98% |
| 2025-03-31 | 15.76B | 17.50% |
| 2024-12-31 | 14.19B | 31.07% |
| 2024-09-30 | 14.24B | 6.81% |

### Comprehensive Analysis
The company has shown significant growth in recent years, with a cumulative return of 281.90%. The stock price has fluctuated in the last 5 days, with a close of $1,081.00 and a 5-day SMA of $1,080.38. The indicators show a market risk indicator of 0.80, RSI of 52.44, and PPO of -0.29. The analysts have a consensus of "Buy" with a mean rating of 1.70. The recent earnings analysis shows an increase in revenue and profit margin. However, the equity and ROE have fluctuated in the past quarters. Overall, the company's financial performance indicates a strong growth potential.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.